tbuckley/cabot-search huggingface dataset:
PRACTICE ACTS AND RELIGIOUS LIBERTY.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Current applications of multiparameter flow cytometry in plasma cell disorders
Authors: T Jelinek, R Bezdekova, M Zatopkova, L Burgos, M Simicek, T Sevcikova, B Paiva, R Hajek
Journal: Blood Cancer Journal (2018)

Correction to: Blood Cancer Journal (2017) 7, e617; doi:10.1038/bcj.2017.90; published online 20 October 2017 Since the publication of this paper the authors have noticed that some of the references cited in the text were not numbered correctly. A duplicate reference in the reference list was removed during the production process but the references were not correctly re-numbered in the text.
NICHOLAS CULPEPER (1616-1654) —PHYSICIAN-ASTROLOGER
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Monatsschrift fur Kinderheilkunde, Berlin
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Endocrinology
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment outcome according to tumor <i>RAS</i> mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
Authors: Fortunato Ciardiello, Heinz-Josef Lenz, Claus-Henning Kohne, Volker Heinemann, Sabine Tejpar, Ivan Melezinek, Frank Beier, Christopher Stroh, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2014)

3506 Background: The addition of cetuximab to FOLFIRI significantly improved progression-free survival, overall survival and response in the first-line treatment of patients (pts) with KRAS codon 12/13 (hereinafter exon 2) wild-type (wt) mCRC. Pts with KRAS exon 2 tumor mutations showed no cetuximab treatment benefit. Methods: Available KRAS exon 2 wt tumors from CRYSTAL study pts were screened for 26 mutations (new RAS) in 4 additional KRAS codons (exons 3 and 4) and 6 NRAS codons (exons 2, 3 and 4) using BEAMing technology (5% sensitivity cutoff selected for analysis). Outcome was assessed according to RAS mutation status (KRAS exon 2 + new RAS). Results: Mutation status was evaluable in 430/666 (65%) pts with KRAS exon 2 wt tumors. New RAS mutations were detected in 63/430 (15%) pts. In those with RAS wt tumors, a significant benefit across all endpoints was associated with the addition of cetuximab to FOLFIRI (Table). In pts with new RAS tumor mutations, no clear difference in efficacy outcomes between treatment groups was seen. In pts with any tumor RAS mutation (KRAS exon 2 + new RAS), no benefit from the addition of cetuximab to FOLFIRI was apparent. Conclusions: In the first-line treatment of mCRC, pts with RAS wt tumors derived a marked benefit from the addition of cetuximab to FOLFIRI; pts with RAS tumor mutations did not benefit. This finding may allow the further tailoring of cetuximab therapy to maximize pt benefit. Clinical trial information: NCT00154102. Parameter RAS wt* (all loci) New RAS mt* RAS mt† (any locus) FOLFIRI + cet N=178 FOLFIRI N=189 FOLFIRI + cet N=32 FOLFIRI N=31 FOLFIRI + cet N=246 FOLFIRI N=214 Response rate, % 66.3 38.6 34.4 35.5 31.7 36.0 Odds ratio 3.11 1.02 0.85 95% CI 2.03–4.78 0.33–3.15 0.58–1.25 P value‡ <0.0001 0.97 0.40 Median progression-free survival, months 11.4 8.4 7.2 6.9 7.4 7.5 HR 0.56 0.81 1.10 95% CI 0.41–0.76 0.39–1.67 0.85–1.42 P value§ 0.0002 0.56 0.47 Median overall survival, months 28.4 20.2 18.2 20.7 16.4 17.7 HR 0.69 1.22 1.05 95% CI 0.54–0.88 0.69–2.16 0.86–1.28 P value§ 0.0024 0.50 0.64 Abbreviations: cet, cetuximab; HR, hazard ratio; mt, mutant; *RAS evaluable population, N=430; †Subset of CRYSTAL KRAS evaluable population, N=1063; ‡Cochran-Mantel-Haenszel; §log-rank.
Heroin and the new prescribers.
Journal: BMJ (1968)

PointersHeroin: Number of new addicts registered in past 20 years steadily rising (p. 725); Of one hundred heroin addicts admitted to hospital 88 sed two other drugs in addition to heroin, 75 had had convictions, 39 had had septic complicadons from drug administration, and 17 had had overdoses (p. 727); High incidence of hepatitis from " syringe sharing " and unclean injection habits, and about half these patients showed evi- dence of liver damage (p.730); Leader, this page.Lung Cancer: Chronic bronchitics seem to be at higher risk than rest of population, and therefore anti-smoking propaganda should be concentrated on this group (p.732).Course of Migraine: In 92 patients followed for 15 to 20 years, over a quarter became symptom-free, and two-thirds of the remainder were improved, but there seemed to be no relation to age, or age of onset, or period of time ince onset (p. 735).Chelanz Drugs: In 16 children accidentally poisoned with iron, these preparations were effective and probably improved the prognosis for survival and morbidity (p.737).IMo in Maternity Unit: E.C.H.O.virtu type 5 causative organism in epidemic febrile Mness in Singapore.Infants mainly affected, but no complications or late sequelae reported (p. 742).Leader at p. 722.Gas Gangrene: In a fatal case, spores from patient's own faeces probably caused contamina- tion, an injection of adrenaline precipitating in- fection (p.744).Leader at p. 721.Short Reports: Platelet factor 4 (p.746); Myelomatosis presenting as dermatomyositis (p.747); XYY constitution in prepubertal child (p.748); Renal failure in paraquat poisoning (p.749).Intestinal Obstructioni: Clinical patterns, causes, and management (p.751).Today's Drugs: Amphetamines and other stimulants (p.753).Ministry warning on amphetamine prescribing (p. 754).
The Lunch Hour at School.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival
Authors: A. R. Casazza
Journal: JAMA (1966)

Infections occur frequently in patients with lymphomas.<sup>1-3</sup>Recurrent staphylococcal infections, gram-negative septicemia, and fungal and viral complications are all relatively more common in patients with hematological malignancies.<sup>4-7</sup> Altered immunological reactivity,<sup>3,8,9</sup>chemotherapy,<sup>5</sup>and corticosteroid therapy<sup>6,10-12</sup>have all been implicated as predisposing factors to infection in these patients. However, no report has correlated these factors and the development of infections with disease duration. Moreover, few studies have analyzed for comparison a group of patients without clinical infection. This report defines and compares the incidence of the types of infections occurring in patients with Hodgkin's disease, mycosis fungoides, lymphosarcoma, and reticulum cell sarcoma. The development of infections was related to the duration of the patients illness. <h3>Materials and Methods</h3> The autopsy and clinical records of all patients with Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma, and mycosis fungoides dying at the National Institutes of Health during the years 1953
Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion
Authors: K.C. Wu, R.J. Kim, D.A. Bluemke, C.E. Rochitte, E.A. Zerhouni, L.C. Becker, J.A.C. Lima
Journal: Journal of the American College of Cardiology (1998)
Hospital-wide program identifies battered women; offers assistance
Authors: T. Randall
Journal: JAMA (1991)

POLICE OFFICERS say that responding to a call involving domestic assault is one of the most dangerous aspects of their work. For physicians, it is no less a challenge. Treating the injury lies comfortably within the realm of medicine, but addressing the injury's cause can feel like trespassing in another's territory. Physicians have been criticized for not asking about the cause of a woman's injuries, even when it is clear that she was deliberately hurt by another person. But if physicians do choose to ask, and discover the patient is a victim of abuse, what can they offer her? Many physicians lack an effective way to connect these women with services that could help. Simply giving her the telephone number of a crisis center is rarely sufficient—battered women are not likely to call these numbers unless they are also receiving ongoing, personal support of some kind. Many are afraid that
Science and Humanity
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HOMEOPATHY
Authors: Nat Kanner
Journal: JAMA (1960)

<h3>To the Editor:—</h3> The article on "Hormoligosis in Pharmacology," by Townsend and Luckey (<i>J. A. M. A.</i><b>173</b>:44 [May 7] 1960) discusses the Arndt-Schulz law, namely, that small drug doses stimulate and that large doses depress. What disappoints me most is that the authors did not give as references any homeopathic pharmacology, because the entire method of homeopathic drug prescribing specifically follows the Arndt-Schulz law. As a matter of fact, the homeopathic concept predates the Arndt-Schulz law, since Samuel Hahnemann, M.D., worked out his laws of homeopathy in his book, "Organon of the Rational Art of Healing," in 1810. His principles have remained essentially the same for the past 150 years. A homeopathic dose is a subphysiological dose, the smallest needed to produce the desired therapeutic effect and cure. Every single "potentiated" or diluted dose, as it is called, has never caused any toxicity or dangerous side-effect in the
Pelvic Varicosities Due to Thrombophlebitis
Authors: Israel Steinberg
Journal: JAMA (1967)

Venography through the common femoral veins demonstrated that dyspareunia following recurrent pelvic, groin, and lower-extremity thrombophlebitis was caused by pelvic varicosities resulting from occlusion of the common iliac veins and inferior vena cava. An adequate collateral circulation via ascending lumbar, vertebral, gonadal (vaginal, uterine, and ovarian), and caval (azygos system)
Resuscitation from ventricular fibrillation. Drug therapy
Authors: J. S. Redding
Journal: JAMA (1968)

In resuscitating dogs subjected to ten minutes of circulatory arrest due to ventricular fibrillation, a number of drugs were used with artificial ventilation of the lungs, external cardiac massage, and external electrical counter-shock. Resuscitation was more successful when epinephrine was used than when no drug therapy or sodium bicarbonate were used. Combination of lidocaine with epinephrine increased the frequency of defibrillation, but circulation was not restored more often than with epinephrine alone. The use of methoxamine hydrochloride was followed by successful resuscitation more often than was the use of epinephrine. Combination of epinephrine and sodium bicarbonate was as effective as methoxamine in restoring circulation, and inspection of the survivors after 24 hours suggested that the combination might be preferable.
Highlights
Journal: JAMA Cardiology (2019)

Association of Statin Adherence With Mortality in ASCVD 206Statin adherence remains suboptimal in patients with atherosclerotic cardiovascular disease (ASCVD).Rodriguez and coauthors examined the association of statin adherence with mortality in patients with ASCVD receiving stable statin prescriptions within the Veterans Affairs Health System between January 2013 and April 2014, with a mean follow-up of 2.9 years.Adherence was higher in patients taking moderate-intensity statins compared with high-intensity statins.Women, minorities, adults younger than 65 years, and adults 75 years and older had lower adherence rates.Compared with the most adherent patients with a medication possession ratio (MPR) of 90% or greater, the adjusted hazard ratio was 1.30 in those with an MPR less than 50%, 1.21 in those with an MPR of 50% to 69%, and 1.08 in those with an MPR of 70% to 89%.
Experimental Infection of the Respiratory Tract with Mycoplasma pneumoniae
Authors: Ping-Chuan Hu, Jerome M. Kirtz, Donald E. Gardner, Dwight A. Powell
Journal: Environmental Health Perspectives (1980)

M. pneumoniae, a common human respiratory pathogen, has been studied experimentally for years using intranasal inoculation of the golden Syrian hamster. Because of recent evidence outlining the role in pulmonary immune development of particle size and depth of mycoplasma deposition in the hamster lung, we developed an aerosol chamber for the reproducible aerosolization of radiolabeled M. pneumoniae. Organisms were labeled to high specific activity by the incorporation of 3H-oleic acid and aerosolized under airflow and humidity conditions creating a mean particle diameter of 2.0 micrometers. Under these conditions, viable mycoplasmas were reproducibly and evenly distributed to all major lobes of the lung. Examination of radioactive clearance and organism viability within the lung during the first 48 hr after aerosolization have suggested a minimal role for macrophage mycoplasmacidal activity and a more prominent role for ciliary clearance. Data from aerosol infections of hamsters with radio-labeled M. pneumoniae should provide a unique opportunity to examine in a highly controlled manner the effects of air pollutants on the initial stages of infection as well as effects on the development of pulmonary immunity and histologic alterations.
Prevention of Toxic Environmental Illness in the Twenty-First Century
Authors: Philip J. Landrigan
Journal: Environmental Health Perspectives (1990)

Previous introductions of new technologies have frequently resulted in unanticipated occupational and environmental illness. Prevention of such illness in the twenty-first century requires stringent application of two fundamental principles of public health: evaluation of new technologies before their introduction, and surveillance of exposed persons after the introduction of new technologies. Failure to establish these basic preventive mechanisms in advance will inevitably result in the development of new toxic diseases in the twenty-first century.
Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study
Authors: A. I. Hjalmarson
Journal: JAMA (1984)

The effect of 2-mg nicotine chewing gum as an adjunct to group therapy for smoking cessation was studied in a placebo-controlled, double-blind, randomized trial. After one year, 29% of the 106 subjects treated with nicotine chewing gum had remained abstinent throughout the year compared with 16% of the 99 subjects treated with placebo. The results were confirmed by measurement of levels of expired CO. More subjects in the nicotine group (70/94<i>v</i>45/93) reported that the gum reduced the craving for smoking. The adverse effects were few and not serious. In the nicotine group, 3% were still using the nicotine gum after two years. No subjects in the placebo group used the chewing gum beyond six months. Nicotine chewing gum is effective in improving the success rates in smoking cessation based on group therapy. (<i>JAMA</i>1984;252:2835-2838)
Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver
Authors: Nurdan Guldiken, Josepmaria Argemi, Berivan Gürbüz, Stephen Atkinson, Karim Hamesch, Joaquin Cabezas, Sheng Cao, Philippe Mathurin, Vijay Shah, Christian Trautwein, Mark Thursz, Ramon Bataller, Pavel Strnad
Journal: Journal of Hepatology (2020)
401. Quantitative Bioluminescence Imaging of Transgene Expression In Vivo
Authors: Garrett R. Rettig, Marie McAnuff, Dijie Liu, Ji-Seon Kim, Kevin G. Rice
Journal: Molecular Therapy (2006)

Bioluminescent imaging (BLI) is a widely used in vivo method to determine the location and relative intensity of luciferase expression in mice. In the present study, we have rigorously validated BLI to establish its utility as a quantitative measurement of luciferase expression for comparing the efficiency of non-viral gene transfer vectors in vivo. Precise quantities of plasmid DNA encoding the luciferase gene were hydrodynamically dosed in mice and luciferase expression was measured at different time intervals following an i.p. dose of D-luciferin. BLI provided a linear response when dosing 100 pg to 5 mg of plasmid DNA and integrating the light units measured in liver, resulting in a dynamic range that spanned 5- orders of magnitude. The level of luciferase expression was found to be a direct function of D-luciferin dose. BLI was used to serially sample mice to determine the time course of luciferase expression and to establish the influence of multi-dosing of substrate. BLI was found to be just as sensitive as a standard luciferase assay applied to homogenized mouse liver. The results establish a limit-of-detection of 20 pg of luciferase/liver following a hydrodynamic dose of 100 pg of plasmid DNA. BLI was also utilized to quantify the efficiency of knockdown of gene expression following siRNA dosing. The results demonstrate that BLI is both sensitive and linear and allows for the direct comparison of the efficiency of gene transfer vectors that target the liver.